

Ralf Regenthal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5885317/publications.pdf>

Version: 2024-02-01

61
papers

2,266
citations

279798

23
h-index

223800

46
g-index

76
all docs

76
docs citations

76
times ranked

3548
citing authors

#	ARTICLE	IF	CITATIONS
1	Prefrontal Cortex Activation and Stopping Performance Underlie the Beneficial Effects of Atomoxetine on Response Inhibition in Healthy Volunteers and Those With Cocaine Use Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2022, 7, 1116-1126.	1.5	6
2	Mapping the effects of atomoxetine during response inhibition across cortical territories and the locus coeruleus. <i>Psychopharmacology</i> , 2022, 239, 365-376.	3.1	2
3	One-week escitalopram intake alters the excitation-inhibition balance in the healthy female brain. <i>Human Brain Mapping</i> , 2022, 43, 1868-1881.	3.6	11
4	A Pharmacokinetic and Metabolism Study of the TRPC6 Inhibitor SH045 in Mice by LC-MS/MS. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3635.	4.1	0
5	Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers. <i>PLoS ONE</i> , 2022, 17, e0266897.	2.5	1
6	Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes. <i>PLoS Computational Biology</i> , 2022, 18, e1010079.	3.2	19
7	Characterization of Drug Release from Mesoporous SiO ₂ -Based Membranes with Variable Pore Structure and Geometry. <i>Pharmaceutics</i> , 2022, 14, 1184.	4.5	2
8	Modulation of premotor cortex response to sequence motor learning during escitalopram intake. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1449-1462.	4.3	3
9	Validation of an LC-MS/MS Method to Quantify the New TRPC6 Inhibitor SH045 (Larixyl) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50</i> <i>Pharmaceutics</i> , 2021, 14, 259.	3.8	3
10	Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease. <i>Brain</i> , 2021, 144, 2513-2526.	7.6	53
11	A single dose of escitalopram blunts the neural response in the thalamus and caudate during monetary loss. <i>Journal of Psychiatry and Neuroscience</i> , 2021, 46, E319-E327.	2.4	3
12	Expression of muscarinic acetylcholine receptors in turkey cardiac chambers. <i>Research in Veterinary Science</i> , 2021, 136, 602-608.	1.9	1
13	Decreased thalamo-cortico connectivity during an implicit sequence motor learning task and 7 days escitalopram intake. <i>Scientific Reports</i> , 2021, 11, 15060.	3.3	1
14	The Rho kinase (ROCK) inhibitor Y-27632 reduces the β_2 -adrenoceptor density but enhance cAMP formation in primary equine bronchial epithelial cells. <i>European Journal of Pharmacology</i> , 2021, 907, 174323.	3.5	0
15	Nutraceuticals in mental diseases – Bridging the gap between traditional use and modern pharmacology. <i>Current Opinion in Pharmacology</i> , 2021, 61, 62-68.	3.5	1
16	Presence and function of β_2 -adrenergic receptors in primary equine bronchial epithelia cells. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 61, 101897.	2.6	1
17	Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2020, 58, 426-438.	0.6	14
18	Appropriate antibiotic prescribing among final-year medical students in Europe. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 375-379.	2.5	14

#	ARTICLE	IF	CITATIONS
19	Potential Drug Interactions Forgotten. Deutsches Ärzteblatt International, 2019, 116, 71-72.	0.9	0
20	Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. Clinical Pharmacology and Therapeutics, 2018, 104, 317-325.	4.7	46
21	Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation. Drug Design, Development and Therapy, 2018, Volume 12, 3653-3664.	4.3	13
22	Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans. Neuropsychopharmacology, 2018, 43, 2645-2651.	5.4	72
23	Search for an animal model to investigate selective pulmonary vasodilation. Laboratory Animals, 2017, 51, 376-387.	1.0	0
24	Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [11C] DASB positron emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1096-1104.	6.4	22
25	Atomoxetine restores the response inhibition network in Parkinsonâ€™s disease. Brain, 2016, 139, 2235-2248.	7.6	76
26	The effect of serum BDNF levels on central serotonin transporter availability in obese versus non-obese adults: A [11C]DASB positron emission tomography study. Neuropharmacology, 2016, 110, 530-536.	4.1	13
27	Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Human Brain Mapping, 2016, 37, 1026-1037.	3.6	60
28	In-vivo serotonin transporter availability and somatization in healthy subjects. Personality and Individual Differences, 2016, 94, 354-359.	2.9	3
29	Improving response inhibition systems in frontotemporal dementia with citalopram. Brain, 2015, 138, 1961-1975.	7.6	71
30	P.6.d.014 Investigating â€˜waiting impulsivityâ€™ in cocaine addiction: are the effects of atomoxetine mediated by genotype?. European Neuropsychopharmacology, 2015, 25, S619.	0.7	0
31	Improving Response Inhibition in Parkinsonâ€™s Disease with Atomoxetine. Biological Psychiatry, 2015, 77, 740-748.	1.3	93
32	Fulminant thrombotic thrombocytopenic purpura (TTP): association with amphetamine consumption?. Annals of Hematology, 2015, 94, 337-338.	1.8	2
33	Altered serotonin transporter availability in patients with multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 827-835.	6.4	56
34	Serotonergic Modulation of Intrinsic Functional Connectivity. Current Biology, 2014, 24, 2314-2318.	3.9	82
35	Targeting impulsivity in Parkinsonâ€™s disease using atomoxetine. Brain, 2014, 137, 1986-1997.	7.6	116
36	Selective serotonin reuptake inhibition modulates response inhibition in Parkinsonâ€™s disease. Brain, 2014, 137, 1145-1155.	7.6	113

#	ARTICLE	IF	CITATIONS
37	A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. <i>Brain</i> , 2013, 136, 3252-3270.	7.6	90
38	Metabolic studies of the Amaryllidaceous alkaloids galantamine and lycorine based on electrochemical simulation in addition to in vivo and in vitro models. <i>Analytica Chimica Acta</i> , 2012, 756, 60-72.	5.4	22
39	Dose-dependent emetic effects of the Amaryllidaceous alkaloid lycorine in beagle dogs. <i>Toxicol</i> , 2011, 57, 117-124.	1.6	38
40	In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis. <i>Archives of Toxicology</i> , 2011, 85, 1565-1573.	4.2	23
41	The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 606-617.	2.1	53
42	Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study. <i>Psychopharmacology</i> , 2010, 210, 317-329.	3.1	101
43	Depression-like deficits in rats improved by subchronic modafinil. <i>Psychopharmacology</i> , 2009, 204, 627-639.	3.1	33
44	The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. <i>Psychopharmacology</i> , 2009, 207, 35-45.	3.1	52
45	Atomoxetine Modulates Right Inferior Frontal Activation During Inhibitory Control: A Pharmacological Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2009, 65, 550-555.	1.3	274
46	Effects of oral methylphenidate on [¹⁸ F]fallypride binding in healthy volunteers and adults with attention-deficit hyperactivity disorder (ADHD). <i>Pharmacopsychiatry</i> , 2009, 42, .	3.3	0
47	Plasma level-dependent effects of methylphenidate and modafinil on processing speed and short term memory capacity parameters of the theory of visual attention (TVA) task. <i>Pharmacopsychiatry</i> , 2009, 42, .	3.3	0
48	Aripiprazole and sulpiride have differenzial effects on working memory performance and brain activity in patients with schizophrenia and healthy controls. <i>Pharmacopsychiatry</i> , 2009, 42, .	3.3	0
49	Sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. <i>Pharmacopsychiatry</i> , 2009, 42, .	3.3	0
50	Changes in purinergic signaling after cerebral injury – involvement of glutamatergic mechanisms?. <i>International Journal of Developmental Neuroscience</i> , 2006, 24, 123-132.	1.6	59
51	Plasma kinetics of procarbazine and azo-procarbazine in humans. <i>Anti-Cancer Drugs</i> , 2006, 17, 75-80.	1.4	13
52	Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity. <i>Free Radical Biology and Medicine</i> , 2006, 40, 779-790.	2.9	53
53	D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2005, 43, 370-378.	0.6	13
54	Anticonvulsant Profile of Flunarizine and Relation to Na ⁺ Channel Blocking Effects. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 94, 79-88.	2.5	21

#	ARTICLE	IF	CITATIONS
55	P2 receptors are involved in the mediation of motivation-related behavior. <i>Purinergic Signalling</i> , 2004, 1, 21-29.	2.2	26
56	Effects of modafinil on working memory processes in humans. <i>Psychopharmacology</i> , 2004, 177, 161-169.	3.1	153
57	Evaluation of REMEDI HS in the Diagnosis of Dimethoate Poisoning. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 297-301.	2.0	3
58	In vitro tolerance to inhibition by ethanol of N-methyl-d-aspartate-induced depolarization in locus coeruleus neurons of behaviorally ethanol-tolerant rats. <i>Neurochemistry International</i> , 2001, 39, 51-58.	3.8	17
59	A Novel Cardenolide Photoaffinity Label for the Na/K-ATPase. <i>Tetrahedron</i> , 2000, 56, 9625-9632.	1.9	4
60	Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. <i>Journal of Clinical Monitoring and Computing</i> , 1999, 15, 529-544.	1.6	226
61	Poisoning with tilidine and naloxone: toxicokinetic and clinical observations. <i>Human and Experimental Toxicology</i> , 1998, 17, 593-597.	2.2	8